Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study

E Guttman-Yassky; A Blauvelt; L.F. Eichenfield; A Paller; A Armstrong; J Drew; R Gopalan; E Simpson

doi:10.25251/skin.3.supp.41

E Guttman-Yassky

Icahn School of Medicine at Mount Sinai, New York, NY

A Blauvelt

Oregon Medical Research Center, Portland, OR

L.F. Eichenfield

University of California and Rady Children?s Hospital, San Diego, CA

A Paller

Northwestern University Feinberg School of Medicine, Chicago, IL

A Armstrong

Keck School of Medicine at the University of Southern California, Los Angeles, CA

J Drew

Dermira, Inc., Menlo Park, CA

R Gopalan

Dermira, Inc., Menlo Park, CA

E Simpson

Oregon Health and Science University, Portland, OR

Keywords

atopic dermatitis, lebrikizumab

Abstract

Abstract not available.

References

1. Bieber T. Ann Dermatol. 2010;22(2):125-37.

2. Drucker AM, Wang AR, Li WQ, et al. J Invest Dermatol. 2017;137(1):26-30.

3. Moyle M, Cevikbas F, Harden JL, Guttman-Yassky E. Exp Dermatol. 2019;28(7):756-68.

4. Bieber T. Allergy. 2019. [Epub ahead of print]

5. Tsoi LC, Rodriguez E, Degenhardt F, et al. J Invest Dermatol. 2019; 139(7):1480-89.

6. Simpson EL, Flohr C, Eichenfield LF, et al. J Am Acad Dermatol. 2018;78(5):863-71.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.41

How to Cite

Guttman-Yassky, E., Blauvelt, A., Eichenfield, L., Paller, A., Armstrong, A., Drew, J., Gopalan, R., & Simpson, E. (2019). Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. SKIN The Journal of Cutaneous Medicine, 3, S41. https://doi.org/10.25251/skin.3.supp.41

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Eczema & Xerosis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich, Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
D Tha?i, A Blauvelt, K Reich, RB Warren, V Piguet, F Brock, F Fierens, V Ciaravino, M Lebwohl, Long-Term Improvements in Health-Related Quality of Life of Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Results from the CIMPASI-1 and CIMPASI-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
C Leonardi, K Fahrbach, B Neupane, A Armstrong , K Gordon, S Kiri, V Taieb, L McClung, Number Needed to Treat Among Therapies for Patients with Moderate to Severe Plaque Psoriasis: Clinical Perspective of Results from a Network Meta-Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
A Blauvelt, B Strober, R Langley, D Burge, L Pisenti, M Yassine, S Kavanagh, C Arendt, R Rolleri, K Reich, Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks' Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich, Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
K Gordon, RB Warren, AB Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich, Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2, and CIMPACT) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
A Blauvelt, AB Gottlieb, F Fierens, F Brock, S Wiegratz, H Sofen, Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
A Blauvelt, RB Warren, K Reich, F Brock, F Fierens, V Ciaravino, M Lebwohl, Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
A Blauvelt, RB Warren, K Reich, F Brock, F Fierens, V Ciaravino, M Lebwohl, Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2) , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
L Green, A Armstrong, CF Teller, S Bell, T Lin, Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

<< < 1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)